Technical Analysis for CTOR - Citius Oncology, Inc.

Grade Last Price % Change Price Change
F 0.96 -2.62% -0.03
CTOR closed up 0.62 percent on Wednesday, November 20, 2024, on 35 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction -2.62%
NR7-2 Range Contraction -2.62%
Narrow Range Bar Range Contraction -2.62%
Lower Bollinger Band Walk Weakness -2.62%
Wide Bands Range Expansion -2.62%
Oversold Stochastic Weakness -2.62%
NR7 Range Contraction -2.01%
Narrow Range Bar Range Contraction -2.01%
Lower Bollinger Band Walk Weakness -2.01%
Wide Bands Range Expansion -2.01%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 1 hour ago
Rose Above Previous Day's High about 6 hours ago
Up 3% about 6 hours ago
Down 2 % about 6 hours ago
Down 1% about 6 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Citius Oncology will serve as a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals.
Classification

Keywords: FDA Oncology Therapies

Is CTOR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 49.0
52 Week Low 0.932
Average Volume 142,602
200-Day Moving Average 8.12
50-Day Moving Average 1.26
20-Day Moving Average 1.16
10-Day Moving Average 1.15
Average True Range 0.18
RSI (14) 37.89
ADX 7.3
+DI 18.95
-DI 23.95
Chandelier Exit (Long, 3 ATRs) 0.90
Chandelier Exit (Short, 3 ATRs) 1.48
Upper Bollinger Bands 1.37
Lower Bollinger Band 0.95
Percent B (%b) 0.1
BandWidth 36.71
MACD Line -0.13
MACD Signal Line -0.14
MACD Histogram 0.0111
Fundamentals Value
Market Cap 8.85 Million
Num Shares 8.94 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 4.95
Price-to-Sales 0.00
Price-to-Book 1.41
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.10
Resistance 3 (R3) 1.10 1.06 1.08
Resistance 2 (R2) 1.06 1.03 1.06 1.08
Resistance 1 (R1) 1.03 1.02 1.01 1.03 1.07
Pivot Point 0.99 0.99 0.98 0.99 0.99
Support 1 (S1) 0.95 0.96 0.93 0.95 0.91
Support 2 (S2) 0.91 0.94 0.91 0.90
Support 3 (S3) 0.88 0.91 0.90
Support 4 (S4) 0.88